Immutep (IMM.AX) Stock Price
Immutep Price
Revenue at Immutep has contracted by 19.7% per year over the past 19 years to 60,100.00 AUD. For Immutep, the net margin of -102,220.0% is down versus -9,559.7% a few years ago. The consensus 12-month price target for Immutep is 1.13 AUD, about 2,308.9% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 31% above its 52-week low.
Immutep stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Immutep over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Immutep stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Immutep's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Immutep Price |
|---|---|
| 9/3/2026 | 0.05 AUD |
| 9/2/2026 | 0.05 AUD |
| 9/1/2026 | 0.05 AUD |
| 8/31/2026 | 0.05 AUD |
| 8/28/2026 | 0.05 AUD |
| 8/27/2026 | 0.05 AUD |
| 8/26/2026 | 0.05 AUD |
| 8/25/2026 | 0.05 AUD |
| 8/24/2026 | 0.05 AUD |
| 8/21/2026 | 0.05 AUD |
| 8/20/2026 | 0.05 AUD |
| 8/19/2026 | 0.05 AUD |
| 8/18/2026 | 0.05 AUD |
| 8/17/2026 | 0.05 AUD |
| 8/14/2026 | 0.05 AUD |
| 8/13/2026 | 0.05 AUD |
| 8/12/2026 | 0.05 AUD |
| 8/11/2026 | 0.05 AUD |
| 8/10/2026 | 0.05 AUD |
| 8/7/2026 | 0.05 AUD |
| 8/6/2026 | 0.05 AUD |
| 8/5/2026 | 0.05 AUD |
| 8/4/2026 | 0.05 AUD |
| 8/3/2026 | 0.05 AUD |
| 7/31/2026 | 0.05 AUD |
| 7/30/2026 | 0.05 AUD |
| 7/29/2026 | 0.05 AUD |
| 7/28/2026 | 0.05 AUD |
| 7/27/2026 | 0.05 AUD |
| 7/24/2026 | 0.05 AUD |
Immutep Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Immutep Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB AUD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM AUD |
| EBITM AUD |
| EBIT MARGIN% |
| NET INCOMEM AUD |
| NET INCOME GROWTH% |
| SHARESB |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | 0.01 | 0.01 | 0.01 | – | – | – | – | – | 0.02 | 0.01 | – | 0.29 | 0.91 | 1.12 |
| 100.00 | 100.00 | 75.00 | -14.29 | 116.67 | – | – | – | – | – | – | -78.26 | -40.00 | 9,500.00 | 214.93 | 23.48 |
| -1,600.00 | -800.00 | -457.14 | -533.33 | -246.15 | – | – | – | – | – | -139.13 | -640.00 | -1,066.67 | -11.11 | -3.53 | -2.86 |
| -32.00 | -32.00 | -32.00 | -32.00 | -32.00 | -13.00 | -26.00 | -32.00 | -32.00 | -32.00 | -32.00 | -32.00 | -32.00 | -32.00 | -32.00 | -32.00 |
| -62.00 | -9.00 | -11.00 | -18.00 | -14.00 | -24.00 | -38.00 | -48.00 | -50.00 | -70.00 | -23.00 | -5.00 | -3.00 | -288.00 | -907.00 | – |
| -3,100.00 | -225.00 | -157.14 | -300.00 | -107.69 | – | – | – | – | – | -100.00 | -100.00 | -100.00 | -100.00 | -100.00 | – |
| -62.00 | -9.00 | -12.00 | -18.00 | -13.00 | -29.00 | -32.00 | -39.00 | -42.00 | -61.00 | -50.00 | -22.00 | -32.00 | -67.00 | -86.00 | 361.00 |
| 93.75 | -85.48 | 33.33 | 50.00 | -27.78 | 123.08 | 10.34 | 21.88 | 7.69 | 45.24 | -18.03 | -56.00 | 45.45 | 109.38 | 28.36 | -519.77 |
| 0.23 | 0.21 | 0.26 | 0.32 | 0.41 | 0.61 | 0.87 | 0.90 | 1.21 | 1.46 | 1.46 | 1.46 | 1.46 | 1.46 | 1.46 | 1.46 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Immutep generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Immutep retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Immutep's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Immutep has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Immutep's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Immutep stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Immutep Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Immutep business model & stock analysis
Immutep SWOT Analysis
Strengths
Immutep Ltd has a strong portfolio of potential immunotherapy drugs, which have shown promising results in early stage trials. These drugs have the potential to revolutionize cancer treatment by enhancing the body's immune response to fight the disease.
The company has a highly skilled and experienced research and development team, bolstered by collaborations with renowned research institutions and academic partners. This allows Immutep to stay at the forefront of immunotherapy research and develop innovative solutions.
Immutep also possesses valuable intellectual property rights and patents, providing a competitive advantage in the rapidly growing immunotherapy market.
Weaknesses
Immutep Ltd currently relies heavily on investment and partnership funding to support its research and development efforts. A lack of diversification in funding sources could pose a risk if there are any disruptions or limitations in securing such funds.
Due to the highly specialized nature of immunotherapy, there is a risk of potential regulatory hurdles and lengthy approval processes before Immutep's drugs can be commercialized and generate revenue.
As a relatively small and emerging biopharmaceutical company, Immutep may face challenges in scaling up manufacturing capabilities and establishing a global presence to effectively compete with larger industry players.
Opportunities
The growing demand for effective cancer treatment options, especially those that harness the power of the immune system, presents a significant market opportunity for Immutep Ltd. The increasing prevalence of cancer worldwide further strengthens this potential market.
Immutep's partnerships with established pharmaceutical companies can provide access to additional resources, expertise, and distribution capabilities, facilitating the development and commercialization of its immunotherapy drugs.
Expansion into new geographic markets and diversifying the application of immunotherapy drugs beyond cancer, such as autoimmune diseases, could open up further revenue streams for the company.
Threats
The competitive landscape in the immunotherapy market is intense, with numerous companies investing heavily in research and development. Immutep Ltd faces the risk of being outpaced by competitors with more advanced therapies or greater financial resources.
Market volatility and regulatory changes can impact investment sentiment and funding availability, which may affect Immutep's ability to continue its research and development activities at the desired pace.
There is also the potential risk of unforeseen side effects or limited efficacy in clinical trials, which could hinder the approval and commercial success of Immutep's immunotherapy drugs.
Immutep Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Immutep historical P/E ratio, EBIT multiple, and P/S ratio
Immutep annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Immutep shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Immutep stock splits
Current Immutep forecasts and price targets in September 2026
Analyst Price Targets 2026Immutep Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 2/22/2024 | -0.02AUD | - | 1.06 MAUD | - | 2024 Q2 |
| 8/29/2023 | 0.12AUD | - | 0.00AUD | - | 2023 Q4 |
| 2/21/2023 | -0.02AUD | - | 0.00AUD | - | 2023 Q2 |
| 7/28/2022 | -0.02AUD | - | 1.35 MAUD | - | 2022 Q4 |
| 2/23/2022 | -0.02AUD | - | 3.04 MAUD | - | 2022 Q2 |
| 8/21/2018 | -0.02AUD | - | 1.70 MAUD | - | 2018 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Immutep stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Immutep shareholder structure
| % | Name |
|---|---|
15.86031% | |
2.27118% | |
1.70952% | |
0.94743% | |
0.70435% | |
0.66287% |
Immutep Executives and Management Board
9 members · 44 % women
Mr. Marc Voigt
Chief Executive Officer, Executive Director · since 2012
1.06 M AUD
Management
Mr. Florian Vogl
Chief Medical Officer
Dr. Frederic Triebel
Chief Scientific Officer, Executive Director · since 2014
Ms. Deanne Miller
Chief Operating Officer, General Counsel, Joint Company Secretary
Ms. Indira Naidu
Joint Company Secretary
Ms. Catherine Strong
Investor Relations · since 2019
Board of Directors
Dr. Russell Howard
Independent Non-Executive Chairman of the Board
Ms. Lis Boyce
Non-Executive Director
Mr. Peter Meyers
Independent Non-Executive Deputy Chairman of the Board
Immutep Supply Chain
Immutep Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.77 | 0.51 | 0.81 | ||
| 2 | 0.36 | 0.75 | 0.81 | ||
| 3 | 0.66 | 0.37 | 0.76 | ||
| 4 | 0.87 | 0.64 | 0.72 | ||
| 5 | 0.48 | 0.52 | 0.71 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.37 | -0.70 | -0.17 | ||
| 2 | -0.48 | -0.30 | -0.03 | ||
| 3 | -0.68 | -0.23 | 0.01 |
Frequently asked questions about Immutep
The business model of Immutep Ltd revolves around developing and commercializing immunotherapy treatments. Immutep Ltd focuses on the development of LAG-3 related products, which play a crucial role in regulating the immune system. By leveraging its expertise and technology, the company aims to treat a wide range of diseases, including cancer and autoimmune disorders. Immutep Ltd collaborates with various partners and conducts clinical trials to evaluate the safety and effectiveness of its therapies. Through strategic partnerships and licensing agreements, the company aims to bring its innovative treatments to market, ultimately improving patient outcomes and advancing the field of immunotherapy.
Immutep Ltd is primarily active in the biotechnology and healthcare industries.
The main competitors of Immutep Ltd in the market include companies like Bristol-Myers Squibb, AstraZeneca, Merck, Roche, and Novartis. These companies also operate in the biopharmaceutical sector and focus on developing innovative treatments and therapies. Immutep Ltd differentiates itself through its unique therapeutic pipeline and commitment to the development of immunotherapies. With their focus on immunomodulation and immuno-oncology, Immutep Ltd aims to make a significant impact in the field of cancer treatment and autoimmune diseases, setting itself apart from its competitors.
Immutep Ltd is an Australian biotechnology company specializing in developing immunotherapy treatments for cancer and autoimmune diseases. Established in 2001, Immutep has a rich history of pioneering research and significant advancements in the field of immune-based therapies. The company's extensive expertise lies in the development of its lead product candidate, eftilagimod alpha (efti), a soluble LAG-3 protein aimed at enhancing immune responses. Immutep Ltd has collaborated with renowned pharmaceutical companies and research institutions worldwide, reinforcing its dedication to advancing immunotherapy and ultimately improving patient outcomes. With a strong focus on innovation, Immutep continues to make significant contributions in the immunotherapy space, propelling the fight against cancer and autoimmune diseases forward.
Immutep Ltd, a leading biotechnology company, has achieved several significant milestones. Firstly, the company successfully completed a Phase IIb clinical trial for its flagship product, Eftilagimod Alpha (efti). The trial demonstrated promising results in treating metastatic breast cancer. Secondly, Immutep entered into a strategic collaboration with major pharmaceutical companies to further develop and commercialize efti. This collaboration enhances its growth potential and market reach. Additionally, Immutep received Fast Track designation from the U.S. FDA for efti, expediting its regulatory process. These accomplishments showcase Immutep Ltd's dedication to advancing breakthrough immunotherapies and solidify its position in the biotech industry.
Immutep Ltd is primarily present in several countries and regions worldwide. These include Australia, where the company is headquartered, as well as the United States, Europe, and Asia-Pacific. With a focus on developing novel immunotherapy treatments, Immutep Ltd has established a global presence to reach patients and collaborate with healthcare and bio-pharmaceutical partners across these regions.
Immutep Ltd is a leading biotechnology company that focuses on developing novel immunotherapeutic treatments. The company is dedicated to improving the lives of patients with cancer and autoimmune diseases through innovative research and development. Immutep's core values revolve around scientific excellence, integrity, and patient-centricity. With a commitment to advancing cutting-edge therapies, Immutep embraces a corporate philosophy centered on collaboration, innovation, and delivering breakthrough solutions. By harnessing the power of the immune system, Immutep aims to revolutionize the way diseases are treated, offering hope and improved outcomes to patients worldwide.
Analysts currently set an average price target of 1.28 AUD for the Immutep stock (median: 1.13 AUD), implying +2,562.8 % versus the latest price. The consensus is based on 9 analyst ratings.
10 analysts currently rate the Immutep stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Immutep to generate revenue of 23.63 M AUD and earnings per share of -0.03 AUD.
Converted at the current exchange rate, the Immutep share trades at 0.03 EUR (0.05 AUD).
The Immutep share (IMM.AX) is listed on 4 stock exchanges, including: Frankfurt (YP1B.F), München (YP1B.MU), ASX (IMM.AX).
Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. The company has two main product platforms, the Lymphocyte Activation Gene (LAG)-3 platform and the IMP321 platform. Its leading products are IMP321, an agonistic LAG-3 antibody, and eftilagimod alpha, an IMP321-based immunotherapy. Immutep also offers services for preclinical and clinical development of immunotherapies. The company has partnerships with pharmaceutical companies such as Novartis, GlaxoSmithKline, and Eddingpharm. It has a portfolio of patents and intellectual property in the LAG-3 and IMP321 areas, and has licensed its LAG-3 technology for predictive diagnostics in cancer patients. Overall, Immutep aims to research, develop, and market immunotherapies for the treatment of cancer and autoimmune diseases, as well as provide services for their development. It positions itself as a leading provider of immunotherapies based on LAG-3 and IMP321 technologies. The answer: Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. It has two main product platforms, LAG-3 and IMP321. Leading products include IMP321 and eftilagimod alpha. The company also offers services for preclinical and clinical development of immunotherapies. It has partnerships with Novartis, GlaxoSmithKline, and Eddingpharm. Immutep has patents and intellectual property in the LAG-3 and IMP321 areas. It has licensed its LAG-3 technology for predictive diagnostics in cancer patients. Overall, Immutep aims to research, develop, and market immunotherapies for cancer and autoimmune diseases, as well as provide development services. It positions itself as a leading provider of immunotherapies based on LAG-3 and IMP321 technologies.
The expected revenue of Immutep is 23.63 M AUD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Immutep is -50.52 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Immutep is currently -1.35. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Immutep stock.
The price-to-sales ratio (P/S) of Immutep is currently 2.90. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Immutep stock.
The Eulerpool Quality Score for Immutep is 2/10.
The ISIN of Immutep is AU000000IMM6. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Immutep is A2H81H. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Immutep is IMM.AX. The ticker symbol is used to trade Immutep shares on the stock exchange.
Immutep paid dividends every year for the past 0 years.
Immutep is assigned to the 'Health' sector.
The dividends of Immutep are distributed in AUD.
Immutep stock
Immutep Peer Group
Immutep Ticker
Immutep FIGI
All fundamentals and in-depth analysis of Immutep
Our stock analysis for Immutep stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immutep. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.